Filters: keyword is derivatives [Clear All Filters]
- 2008
Impact of efflux transporters and of seizures on the pharmacokinetics of oxcarbazepine metabolite in the rat brain,
Br J Pharmacol, vol. 155, no. 7, pp. 1127-38.
- 2007
Pharmacokinetic-pharmacodynamic modeling of the respiratory depressant effect of norbuprenorphine in rats,
J Pharmacol Exp Ther, vol. 321, no. 2, pp. 598-607.
- 2006
Pharmacokinetics and pharmacodynamics analysis of transdermal iontophoresis of 5-OH-DPAT in rats: in vitro-in vivo correlation,
J Pharm Sci, vol. 95, no. 7, pp. 1570-85.
- 2005
Pharmacokinetic/pharmacodynamic modelling of the anti-hyperalgesic and anti-nociceptive effect of adenosine A1 receptor partial agonists in neuropathic pain,
Eur J Pharmacol, vol. 514, no. 2-3, pp. 131-40.
Transdermal iontophoresis of the dopamine agonist 5-OH-DPAT in human skin in vitro,
J Control Release, vol. 103, no. 2, pp. 393-403.
Brain penetration of synthetic adenosine A1 receptor agonists in situ: role of the rENT1 nucleoside transporter and binding to blood constituents,
Eur J Pharm Sci, vol. 24, no. 1, pp. 59-66.
Population pharmacokinetics of lorazepam and midazolam and their metabolites in intensive care patients on continuous venovenous hemofiltration,
Am J Kidney Dis, vol. 45, no. 2, pp. 360-71.
- 2004
Population pharmacokinetic-pharmacodynamic modelling of the anti-hyperalgesic effect of 5'deoxy-N6-cylopentyladenosine in the mononeuropathic rat,
Eur J Pharmacol, vol. 504, no. 1-2, pp. 7-15.
Population pharmacokinetic modeling of blood-brain barrier transport of synthetic adenosine A1 receptor agonists,
J Pharmacol Exp Ther, vol. 311, no. 3, pp. 1138-46.
- 2003
Cyclopentyladenosine and some of its low-efficacy derivatives inhibit striatal synaptosomal release of acetylcholine to a similar degree,
Eur J Pharmacol, vol. 481, no. 2-3, pp. 141-6.
Blood-brain barrier transport of synthetic adenosine A1 receptor agonists in vitro: structure transport relationships,
Eur J Pharm Sci, vol. 20, no. 3, pp. 347-56.
Low efficacy adenosine A1 agonists inhibit striatal acetylcholine release in rats improving central selectivity of action,
Neurosci Lett, vol. 343, no. 1, pp. 57-61.
Functional role of adenosine receptor subtypes in the regulation of blood-brain barrier permeability: possible implications for the design of synthetic adenosine derivatives,
Eur J Pharm Sci, vol. 19, no. 1, pp. 13-22.
Adenosine A1 receptor agonist N6-cyclopentyladenosine affects the inactivation of acetylcholinesterase in blood and brain by sarin,
J Pharmacol Exp Ther, vol. 304, no. 3, pp. 1307-13.
- 2002
Therapeutic efficacy of the adenosine A1 receptor agonist N6-cyclopentyladenosine (CPA) against organophosphate intoxication,
Arch Toxicol, vol. 76, no. 11, pp. 650-6.
Correlation between midazolam and lignocaine pharmacokinetics and MEGX formation in healthy volunteers,
Br J Clin Pharmacol, vol. 53, no. 2, pp. 133-9.
Pharmacokinetic-pharmacodynamic modeling of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine in rats,
J Pharmacol Exp Ther, vol. 303, no. 3, pp. 1130-7.
- 2000
- 1999
Characterization of the pharmacodynamic interaction between parent drug and active metabolite in vivo: midazolam and alpha-OH-midazolam,
J Pharmacol Exp Ther, vol. 289, no. 2, pp. 1067-74.
Mechanism-based pharmacokinetic-pharmacodynamic modeling of antilipolytic effects of adenosine A(1) receptor agonists in rats: prediction of tissue-dependent efficacy in vivo,
J Pharmacol Exp Ther, vol. 290, no. 2, pp. 702-9.
- 1998
Metabolic and cardiovascular effects of the adenosine A1 receptor agonist N6-(p-sulfophenyl)adenosine in diabetic Zucker rats: influence of the disease on the selectivity of action,
J Pharmacol Exp Ther, vol. 287, no. 1, pp. 21-30.
Selectivity of action of 8-alkylamino analogues of N6-cyclopentyladenosine in vivo: haemodynamic versus anti-lipolytic responses in rats,
Br J Pharmacol, vol. 124, no. 3, pp. 607-18.
- 1997
Analysis of drug-receptor interactions in vivo: a new approach in pharmacokinetic-pharmacodynamic modelling,
Int J Clin Pharmacol Ther, vol. 35, no. 10, pp. 442-6.
Pharmacokinetic-pharmacodynamic modelling of the anti-lipolytic and anti-ketotic effects of the adenosine A1-receptor agonist N6-(p-sulphophenyl)adenosine in rats,
Br J Pharmacol, vol. 122, no. 3, pp. 525-33.
Assay of R-apomorphine, S-apomorphine, apocodeine, isoapocodeine and their glucuronide and sulfate conjugates in plasma and urine of patients with Parkinson's disease,
J Chromatogr B Biomed Sci Appl, vol. 702, no. 1-2, pp. 131-41.



